Medical oncology: Optimizing chemotherapy and radiotherapy for anaplastic glioma

Nature Reviews Clinical Oncology

Volumn 7, Issue 8, 2010, Pages 428-430

  Morris, Patrick G ^a   Lassman, Andrew B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RESEARCH; CANCER SURVIVAL; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL TRIAL; GENE MUTATION; GLIOBLASTOMA; HUMAN; INDIVIDUALIZATION; INTERMETHOD COMPARISON; METHODOLOGY; NEUROSURGERY; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN METHYLATION; SHORT SURVEY; TREATMENT FAILURE; TREATMENT OUTCOME;

BRAIN NEOPLASMS; CARCINOMA; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GENE DELETION; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; PROGNOSIS; PROMOTER REGIONS, GENETIC; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 77955132987     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.98     Document Type: Short Survey

References (10)

1. Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase iii study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459-466 (2009).
2. van den Bent, M. J. et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organization for Research and Treatment of Cancer phase III trial. J. Clin. Oncol. 24, 2715-2722 (2006).
3. Cairncross, G. et al. Phase iii trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: intergroup Radiation Therapy Oncology Group Trial. J. Clin. Oncol. 24, 2707-2714 (2006).
4. Wick, W. et al. N0A-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J. Clin. Oncol. 27, 874-880 (2009).
5. van den Bent, M. J. et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin. Cancer Res. 16, 1597-1604 (2010).
6. DeAngelis, L. M. Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected]. J. Clin. Oncol. 27, 861-862 (2009).
7. Cairncross, G. et al. A randomized trial of chemotherapy plus radiotherapy (RT) versus RT alone for anaplastic oligodendroglioma (RTOG 9402): the perspective of longer follow-up [abstract 16]. Int. J. Radiat. Oncol. Biol. Phys. 72, s7-s8 (2008).
8. Abrey, L. E. et al. Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro-oncol. 9, 314-318 (2007).
9. US National Library of Medicine. ClinicalTrials. gov [online], http://www.clinicaltrials.gov/ct2/ show/NCT00887146 (2010).
10. US National Library of Medicine. ClinicalTrials. gov [online], http://clinicaltrials.gov/ct2/ show/NCT00626990 (2010).